List of signals discussed at PRAC since September 2012
Submitted by Anonymous (not verified) on 3 August 2026 - 12:00
List of signals discussed at PRAC since September 2012
Enpr-EMA Coordinating Group meeting June 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, 17 June 2026
Submitted by Anonymous (not verified) on 3 August 2026 - 12:00
Enpr-EMA Coordinating Group meeting June 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, 17 June 2026
Breakthrough status request: Template for applicants for breakthrough medical devices pilot
Submitted by Anonymous (not verified) on 3 August 2026 - 11:55
Breakthrough status request: Template for applicants for breakthrough medical devices pilot
Fifth European Medicines Agency (EMA) and Affordable Medicines Europe bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, 11 September 2026
Submitted by Anonymous (not verified) on 3 August 2026 - 11:00
Fifth European Medicines Agency (EMA) and Affordable Medicines Europe bilateral meeting, Online, European Medicines Agency, Amsterdam, the Netherlands, 11 September 2026
Organisation chart: Veterinary Medicines
Submitted by Anonymous (not verified) on 3 August 2026 - 9:40
Organisation chart: Veterinary Medicines
Human medicines European public assessment report (EPAR): Multaq, dronedarone, Date of authorisation: 25/11/2009, Revision: 23, Status: Authorised
Submitted by Anonymous (not verified) on 31 July 2026 - 10:28
Human medicines European public assessment report (EPAR): Multaq, dronedarone, Date of authorisation: 25/11/2009, Revision: 23, Status: Authorised
Human medicines European public assessment report (EPAR): Aspaveli, pegcetacoplan, Date of authorisation: 13/12/2021, Revision: 14, Status: Authorised
Submitted by Anonymous (not verified) on 31 July 2026 - 9:48
Human medicines European public assessment report (EPAR): Aspaveli, pegcetacoplan, Date of authorisation: 13/12/2021, Revision: 14, Status: Authorised
Start of procedure: Type II Variation - Extension of indication under evaluation by the CHMP (26 June 2026 - 23 July 2026)
Submitted by Anonymous (not verified) on 31 July 2026 - 8:41
Start of procedure: Type II Variation - Extension of indication under evaluation by the CHMP (26 June 2026 - 23 July 2026)
Start of procedure: Extension of marketing authorisation (26 June 2026 - 23 July 2026)
Submitted by Anonymous (not verified) on 31 July 2026 - 8:39
Start of procedure: Extension of marketing authorisation (26 June 2026 - 23 July 2026)
New leadership team appointments
Submitted by Anonymous (not verified) on 30 July 2026 - 16:27
New leadership team appointments